Krystal Biotech Director Executes $10.1M Stock Sale, Exercises Options Under 10b5-1 Plan
Krystal Biotech director Daniel Janney sold 37,825 shares of common stock on February 24, 2026, generating $10,113,353 in proceeds, and also sold 13,666 shares indirectly owned by Alta Bioequities, L.P. for $6,036,029. Janney simultaneously exercised options to acquire 37,895 shares at $2.46 per share under a Rule 10b5-1 trading plan.